BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1133 related articles for article (PubMed ID: 3287933)

  • 1. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic impact of oral contraceptives.
    Krauss RM; Burkman RT
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral contraceptives and cardiovascular risk. Taking a safe course of action.
    Derman RJ
    Postgrad Med; 1990 Sep; 88(4):119-22. PubMed ID: 2204902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease.
    Gaspard UJ; Lefebvre PJ
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):334-43. PubMed ID: 2196805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U
    Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contraception for women with diabetes: an update.
    Skouby SO; Mølsted-Pedersen L; Petersen KR
    Baillieres Clin Obstet Gynaecol; 1991 Jun; 5(2):493-503. PubMed ID: 1954724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary heart disease risk markers in users of low-dose oral contraceptives.
    Godsland IF; Crook D; Wynn V
    J Reprod Med; 1991 Mar; 36(3 Suppl):226-37. PubMed ID: 2046076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
    Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
    Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
    Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of desogestrel on carbohydrate metabolism.
    Shoupe D
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1041-7. PubMed ID: 8447358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Worthington M; Proudler AJ; Felton C; Sidhu M; Stevenson JC
    Contraception; 1993 Sep; 48(3):217-27. PubMed ID: 8222652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the metabolic effects of steroidal contraceptives.
    Sondheimer SJ
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):911-23. PubMed ID: 1778182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.